Medical Advocates
HAART/ART
 
HAART/ART Failure

General Reports
Virological Failure
 Immunological Failure
Mortality/Risk Factors





 
 
HAART Main Page Main New/Newsworthy    Home Page    
Last Update:  April 18, 2012  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
The parametric g-formula to estimate the effect of highly active antiretroviral therapy
on incident AIDS or death.
Westreich D, Cole SR, Young JG,  et al
Stat Med. 2012 Apr 11.
Abstract

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug
experienced people with HIV in Europe.
Nakagawa F.|
 J Acquir Immune Defic Syndr. 2011 Nov 11
 Abstract

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of
antiretroviral treatment failure.
 Paredes R, Lalama CM, Ribaudo HJ, et al
J Infect Dis. 2010 Mar;201(5):662-71.
 Abstract

Evolution of HIV-1 in a patient population failing multiple-drug therapy.
Hong S, Cao J, Tu YT.
 Microbiol Immunol. 2009 Sep;53(9):535-9.
 Abstract

Better than nothing: keeping pts on failing regimen has benefits.
Winslow DL.
 AIDS Alert. 2009 Apr;24(4):44-5.
 Abstract

FULL-TEXT ARTICLE
 Overestimates of Survival after HAART: Implications for Global Scale-Up Efforts.
Bisson GP, Gaolathe T, Gross R, et al 
PLoS ONE. 2008 Mar 5;3(3)
 Paper
 
    Conference Reports, Abstracts, and Posters
 
 
POSTER
Initial CD4 T Lymphocyte Response Is a Strong Predictor of Death in African Cohort Despite
Full Virologic Suppression on HAART at 6 Months
S Takuva, M Maskew, M Fox, et al
(17th CROI)
 PDF Poster    Abstract

Regional disparities in HIV-related deaths and access to HAART: evidence from a province-wide
universal healthcare system
E. Druyts, K.J. Lepik, A. Anemaet al
 (5th IAS Conference)
 Abstract
Virological Failure
     

      Journal Papers, Abstracts, and Commentaries

 
Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and r
isk of virological failure.
Maggiolo F, Callegaro A, Cologni G, et al
 J Acquir Immune Defic Syndr. 2012 Apr 4.
 Abstract

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure
of drugs from three antiretroviral drug classes: a cohort study.
The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational
HIV Epidemiological Research Europe (COHERE) Group
 Lancet Infect Dis. 2011 Oct 7.
 Abstract

FULL-TEXT PDF ARTICLE
 A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients
Undergoing a New Combination Antiretroviral Therapy Regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, et al
BMC Med Inform Decis Mak. 2011 Jun 14;11(1):40. .
 Paper

Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral
Therapy for Up to 10 Years.
The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration
| of Observational HIV Epidemiological Research Europe (COHERE).
Arch Intern Med. 2010 Mar 8;170(5):410-419.
 Abstract

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in
HIV-1-Infected Patients with Virological Failure.
Llibre JM, Schapiro JM, Clotet B
.Clin Infect Dis. 2010 Feb 8.
Abstract

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients
initiating antiretroviral therapy in clinical practice?
The Antiretroviral Therapy Cohort Collaboration (ART-CC).
AIDS. 2008 Nov 30;22(18):2481-2492
 Abstract
 
Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic.
Robbins GK, Daniels B, Zheng H, et al
 J Acquir Immune Defic Syndr. 2006 Nov 9;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL TEXT PDF ARTICLE
 Current concepts in antiretroviral therapy failure.
Del Rio C.
 Top HIV Med. 2006 Aug-Sep;14(3):102-6.
 Paper

Immune Reconstitution and Predictors of Virologic Failure in Adolescents Infected through Risk
Behaviors and Initiating HAART: Week 60 Results from the PACTG 381 Cohort.
 Rudy BJ, Lindsey JC, Flynn PM, et al 
AIDS Res Hum Retroviruses. 2006 Mar;22(3):213-21.
 Abstract
 

     Conference Reports, Abstracts, and Posters

 
 

POSTER
Effect of Initiating Patients on HAART at CD4 Counts above 200 on Virologic Failure and Death
in South Africa: Evidence from the CIPRA-SA Trial
M Fox, I Sanne, F Conradie,  et al
 PDF Poster    Abstract

Predictors of Virological Failure at 6 Months of Therapy in HIV-1-infected Patients
Starting HAART in Porto Alegre, Brazil
 S Tuboi, E Sprinz, L Harrison,  et al
)12 CROI)
Abstract

Trends Over Time in Initial Virological Failure of First HAART: 1996 to 2002.
A Joint Cohort Analysis of 4143 Subjects
 F Lampe, J Gatell, S Staszewski, et al
(12 CROI)
Abstract
Poor Immunological Response/Immunological
Failure
     Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
 KIR-HLA Genotypes in HIV-Infected Patients Lacking Immunological Recovery despite
Effective Antiretroviral Therapy.
Soria A, Guerini FR, Bandera A, et al
PLoS One. 2011;6(11):e27349
 Paper

Immunologic failure despite suppressive antiretroviral therapy is related to activation and
turnover of memory CD4 cells.
Lederman MM, Calabrese L, Funderburg NT, et al
J Infect Dis. 2011 Oct;204(8):1217-26.
 Abstract

Predictors of Immunological Failure after Initial Response to Highly Active
Antiretroviral Therapy in HIV-1-Infected Adults: A EuroSIDA Study.
Dragsted UB, Mocroft A, Vella S, et al 
J Infect Dis. 2004 Jul 1;190(1):148-55.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  Cumulative viremia under HAART predicts long-term clinical outcomes
V.D. Lima, J. Sierra-Madero, Z. Wu, et al
 (6th IAS Conference)
 Abstract

Predictors of poor immune response to highly active antiretroviral therapy in patients
with a sustained virologic response: The Australian HIV Observational Database
1999-2006
 Glenday K, Petoumenos K, Chuah J, et al
 (4th IAS Conference)
 Abstract
Mortality/Risk Factors
     
     Journal Papers, Abstracts, and Commentaries
 
 
Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy,
1996-2006: Collaborative Analysis of 13 HIV Cohort Studies.
[No authors listed]
Clin Infect Dis. 2010 Mar 26.
 Abstract

Racial disparities in HIV virologic failure: do missed visits matter?
Mugavero MJ, Lin HY, Allison JJ, et al 
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):100-8.
 Abstract
 
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between
low-income and high-income countries.
 Braitstein P, Brinkhof MW, Dabis F, et a;
 Lancet. 2006 Mar 11;367(9513):817-24.
 Abstract
 
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance
and abnormal laboratory markers.
 Sabin CA, Smith CJ, Youle M, et al,
AIDS. 2006 Jan 2;20(1):67-71.
 Abstract
 
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy:
1984-2004.
Schneider MF, Gange SJ, Williams CM, et al
AIDS. 2005 Nov 18;19(17):2009-2018.
 Abstract
 
Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy
Is Still Higher Than in Non-HIV-Infected Individuals.
van Sighem A, Danner S, Ghani AC, et al 
J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):212-218
 Abstract

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death:
a prospective cohort study.
Sterne JA, Hernan MA, Ledergerber B,  et al
 Lancet. 2005 Jul 30-Aug 6;366(9483):378-84.
 Abstract
 
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific
antiretroviral drugs in the regimen.
 Olsen CH, Gatell J, Ledergerber B 
AIDS. 2005 Feb 18;19(3):319-330.
 Abstract
 
Causes of death among human immunodeficiency virus (HIV)-infected adults
in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers,
persistent role of AIDS.
 Lewden C, Salmon D, Morlat P, et al.
Int J Epidemiol. 2004 Nov 23;
Abstract

    
     Conference Reports, Abstracts, and Posters
 
 
Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among
adults infected with HIV
 J. Nihau
 (XVI International AIDS Conference)
Abstract
 
Risk factors for early mortality on antiretroviral treatment in a rural hospital in Tanzania
 Johannessen A, Naman E, Matee M, et al
 (4th IAS Conference)
Abstract

Risk of AIDS and Death at Given HIV RNA and CD4 Count Levels, according to
Specific Antiretroviral Drugs in the CART Regimen
 C Holkmann-Olsen, J Gatell, B Ledergerber, et al
 (12 CROI)
Abstract

HIV and Non-HIV-related Deaths and Their Relationship to Immunodeficiency:
The D:A:D Study
 R Weber, N Friis-Møller, C Sabin, et al
(12 CROI)
Abstract
 
HIV Gender Differences in Morbidity and Mortality and the Effect of Aging
 S Hadrigan, M Miguez-Burbano, X Burbano,  et al
(12 CROI)
Abstract
 
Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of
2 Prospective Cohort Studies
 R Hogg, J Lundgren, D Costagliola, et al
(12 CROI)
Abstract

HAART Main Page Main New/Newsworthy    Home Page    

HAART/ART Failure